AGEN-style educational content highlights growing use of high-sensitivity droplet digital PCR (ddPCR) for variant detection and quantification in NSCLC biomarker workflows, including research and translational oncology settings. The material frames ddPCR as a tool for molecular profiling, liquid biopsy testing, and potentially MRD-style monitoring where variant allele detection requires precision. The focus on ultra-sensitive assays reflects continued pressure to measure low-frequency tumor signals reliably, particularly when sample quality or tumor fraction is limiting. It also emphasizes the role of assay quantification in study design and cross-cohort comparisons. For biotech R&D teams, the key message is that ddPCR-style approaches remain central where next-gen sequencing sensitivity and standardization are bottlenecks.